Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 50 条

[41] ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Popat, S.
Tiseo, M.
Gettinger, S.
Peters, S.
Haney, J.
Kerstein, D.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2016, 27
[42] Design of ALTA-1 L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)positive non-small cell lung cancer (NSCLC).
Tiseo, Marcello
Popat, Sanjay
Gettinger, Scott N.
Peters, Solange
Haney, Jeff
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
Nishio, Makoto
Yoshida, Tatsuya
Kumagai, Toru
Hida, Toyoaki
Toyozawa, Ryo
Shimokawaji, Tadasuke
Goto, Koichi
Nakagawa, Kazuhiko
Ohe, Yuichiro
Seto, Takashi
Kudou, Kentarou
Asato, Takayuki
Zhang, Pingkuan
Yamamoto, Nobuyuki
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
[44] Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK plus NSCLC and intracranial metastases in a Phase 1/2 Study
Camidge, D. R.
Bazhenova, L. A.
Salgia, R.
Langer, C. J.
Gold, K.
Rosell, R.
Shaw, A. T.
Weiss, G. J.
Dorer, D. J.
Rivera, V. M.
Conlan, M. G.
Kerstein, D.
Gettinger, S. N.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S616 - S616
[45] Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
Gettinger, S. N.
Bazhenova, L. A.
Salgia, R.
Langer, C. J.
Gold, K.
Rosell, R.
Shaw, A. T.
Weiss, G. J.
Dorer, D. J.
Rivera, V. M.
Kerstein, D.
Camidge, D. R.
LUNG CANCER, 2016, 91 : S20 - S21
[46] Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial (vol 35, pg 2490, 2017)
Paz-Ares, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 931 - 931
[47] Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK plus non-small-cell lung cancer (NSCLC)
Barlesi, F.
Dingemans, A. M. C.
Ou, I.
Ahn, J. S.
Petris, L. D.
Kim, D. W.
Yang, J. C. H.
Hughes, B.
Lena, H.
Moro-Sibilot, D.
Bearz, A.
Viteri, S.
Mekhail, T.
Spira, A.
Zeaiter, A.
Bordogna, W.
Sturm, C.
Golding, S.
Morcos, P. N.
Govindan, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S635 - S635
[48] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.
Huber, Rudolf M.
Kim, Dong-Wan
Ahn, Myung-Ju
Langer, Corey J.
Tiseo, Marcello
West, Howard
Groen, Harry J. M.
Reckamp, Karen L.
Hochmair, Maximilian J.
Leighl, Natasha B.
Hansen, Karin Holmskov
Gettinger, Scott N.
Paz-Ares, Luis G.
Kim, Edward S.
Smit, Egbert F.
Kim, Sang-We
Reichmann, William
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
Tiseo, M.
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Gettinger, S. N.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, R.
ANNALS OF ONCOLOGY, 2022, 33 : S44 - S45
[50] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
Rosell, R.
Gettinger, S. N.
Bazhenova, L. A.
Langer, C. J.
Salgia, R.
Shaw, A. T.
Narasimhan, N. I.
Dorer, D. J.
Kerstein, D.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114

← 1 2 3 4 5 →